Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

22 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Icosapent ethyl modulates circulating vascular regenerative cell content: The IPE-PREVENTION CardioLink-14 trial.
Bakbak E, Krishnaraj A, Bhatt DL, Quan A, Park B, Bakbak AI, Bari B, Terenzi KA, Pan Y, Fry EJ, Terenzi DC, Puar P, Khan TS, Rotstein OD, Mazer CD, Leiter LA, Teoh H, Hess DA, Verma S. Bakbak E, et al. Among authors: puar p. Med. 2024 Mar 27:S2666-6340(24)00121-1. doi: 10.1016/j.medj.2024.03.009. Online ahead of print. Med. 2024. PMID: 38552629
Effect of empagliflozin on cardiac remodelling in South Asian and non-South Asian individuals: insights from the EMPA-HEART CardioLink-6 randomised clinical trial.
Barbour W, Wolff E, Puar P, Hibino M, Bakbak E, Krishnaraj A, Verma R, Verma M, Quan A, Yan AT, Connelly KA, Teoh H, Mazer CD, Verma S. Barbour W, et al. Among authors: puar p. BMC Cardiovasc Disord. 2023 Nov 15;23(1):557. doi: 10.1186/s12872-023-03549-5. BMC Cardiovasc Disord. 2023. PMID: 37964221 Free PMC article. Clinical Trial.
Empagliflozin improves circulating vascular regenerative cell content in people without diabetes with risk factors for adverse cardiac remodeling.
Bakbak E, Verma S, Krishnaraj A, Quan A, Wang CH, Pan Y, Puar P, Mason T, Verma R, Terenzi DC, Rotstein OD, Yan AT, Connelly KA, Teoh H, Mazer CD, Hess DA. Bakbak E, et al. Among authors: puar p. Am J Physiol Heart Circ Physiol. 2023 Nov 1;325(5):H1210-H1222. doi: 10.1152/ajpheart.00141.2023. Epub 2023 Sep 29. Am J Physiol Heart Circ Physiol. 2023. PMID: 37773589 Clinical Trial.
The association between anthropometric indicators of obesity and cardiac reverse remodelling with empagliflozin in patients with type 2 diabetes and coronary artery disease.
Puar P, Ahmed S, Hibino M, Pasricha A, Pandey A, Bari A, Verma R, Quan A, Yan AT, Connelly KA, Teoh H, Mazer CD, Verma S. Puar P, et al. Diabetes Obes Metab. 2023 Sep;25(9):2765-2769. doi: 10.1111/dom.15119. Epub 2023 May 29. Diabetes Obes Metab. 2023. PMID: 37246798 No abstract available.
The Impact of Statins on Postdischarge Atrial Fibrillation After Cardiac Surgery: Secondary Analysis from a Randomized Trial.
Hibino M, Verma S, Pandey AK, Bisleri G, Yanagawa B, Verma R, Puar P, Quan A, Teoh H, Yau TM, Verma A, Ha ACT, Mazer CD; SEARCH-AF Trial Investigators. Hibino M, et al. Among authors: puar p. CJC Open. 2022 Dec 29;5(4):285-291. doi: 10.1016/j.cjco.2022.12.012. eCollection 2023 Apr. CJC Open. 2022. PMID: 37124963 Free PMC article.
22 results